Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107975 | 1.00 | MAPT (0.55) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL2106813 | 0.84 | CYP1A2 (0.54) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL2106816 | 0.84 | CYP1A2 (0.54) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL2107790 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL2107792 | 0.81 | MAPT (0.58) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8837893 | 0.79 | MAPT (0.67) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL8837891 | 0.79 | MAPT (0.67) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL23610389 | 0.76 | MAPT (0.62) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL30714430 | 0.76 | MAPT (0.62) | MAPTALDH1A1HPGDCYP1A2CYP2C19 | |
| SCHEMBL1878680 | 0.75 | MAPT (0.58) | MAPTALDH1A1HPGDCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-12-12 | — | — | US | claimed |
| EP-1899343-B1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INT (ES) | 2010-05-12 | — | — | EP | claimed |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | US | claimed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | claimed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | claimed |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | FERRER INTERNACIONAL, S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACTIONAL, S.A. (ES) | 2016-12-22 | — | — | US | disclosed |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACTIONAL, S.A. (ES) | 2013-12-12 | — | — | US | disclosed |
| US-8530482-B2 | Halogenated pyrazolo[1,5-A]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2013-09-10 | — | — | US | disclosed |
| US-8158632-B2 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| EP-2059521-B1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2010-06-02 | — | — | EP | disclosed |
| EP-2059521-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2009-04-30 | — | — | US | disclosed |
| EP-1899343-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | Ferrer Internacional, S.A. (ES) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008015253-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
| EP-1884516-A1 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006136530-A1 | HALOGENATED PYRAZOLO [1,5-A]PYRIMIDINES, PROCESSES, USES AS GABA-A RECEPTORS LIGAND, COMPOSITIONS AND INTERMEDIATES | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-28 | — | — | WO | disclosed |
| EP-1736475-A1 | Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates | FERRER INTERNACIONAL, S.A. (ES) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331401-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | MAPT 2417/4885ALDH1A1 684/4885HPGD 1521/4885 |
| US-10072000-B2 | Method of treating insomnia with halogenated pyrazolo[1,5-a]pyrimidines | GABRA5, GABRA1, GABBR1 | MAPT 2291/4885ALDH1A1 502/4885HPGD 1729/4885 |
| US-20130331610-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | MAPT 2417/4885ALDH1A1 684/4885HPGD 1521/4885 |
| US-20160368912-A9 | HALOGENATED PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES, COMPOSITIONS AND INTERMEDIATES | GABRA5, GABRA1, RYR1 | MAPT 2417/4885ALDH1A1 684/4885HPGD 1521/4885 |
| US-20090111848-A1 | Halogenated Pyrazolo[1,5-A]Pyrimidines, Processes, Uses, Compositions and Intermediates | GABRA5, GABRA1, RYR1 | MAPT 2417/4885ALDH1A1 684/4885HPGD 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.